David E Ambrose
Overview
Explore the profile of David E Ambrose including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
1768
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Melenhorst J, Chen G, Wang M, Porter D, Chen C, Collins M, et al.
Nature
. 2022 Dec;
612(7941):E22.
PMID: 36477542
No abstract available.
2.
Melenhorst J, Chen G, Wang M, Porter D, Chen C, Collins M, et al.
Nature
. 2022 Feb;
602(7897):503-509.
PMID: 35110735
The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has demonstrated potential for treatment of various cancers. However, little is known about the long-term potential and clonal stability...
3.
Fraietta J, Lacey S, Orlando E, Pruteanu-Malinici I, Gohil M, Lundh S, et al.
Nat Med
. 2021 Feb;
27(3):561.
PMID: 33547459
No abstract available.
4.
Ruella M, Xu J, Barrett D, Fraietta J, Reich T, Ambrose D, et al.
Nat Med
. 2018 Oct;
24(10):1499-1503.
PMID: 30275568
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19 leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into...
5.
Fraietta J, Lacey S, Orlando E, Pruteanu-Malinici I, Gohil M, Lundh S, et al.
Nat Med
. 2018 May;
24(5):563-571.
PMID: 29713085
Tolerance to self-antigens prevents the elimination of cancer by the immune system. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with...
6.
Chong E, Melenhorst J, Lacey S, Ambrose D, Gonzalez V, Levine B, et al.
Blood
. 2016 Dec;
129(8):1039-1041.
PMID: 28031179
No abstract available.